UK contract research company Molecular Profiles has been awarded a Queen's Award for Enterprise in the Continuous Innovation and Development category.
Its services include nanoscreening technology for predicting the ease of development of a new medicine, a deformulation service for identifying problems with a product down to the nanoscale, and advanced imaging for viewing and optimising the internal structure of products.
The Queen's Award for Enterprise recognises Molecular Profiles' unique contract research services, which fall into three key areas: formulation support (including pre-formulation and product r&d); rapid problem solving (during pre-formulation through to manufacturing); and patent and litigation support.
The company is continually developing its range of novel applications based around advanced surface analysis and nanotechnologies, which provide an insight into the chemical, physical and material properties of pharmaceutical and biomedical products. These methods and research are translated into novel solutions that are bespoke to the clients' challenges.
'We are extremely honoured to be awarded this prestigious accolade', said ceo Dr Nikin Patel. 'It is our scientists who develop the rapid response solutions that solve our customers' challenges. This award recognises their expertise and commitment in making Molecular Profiles a cutting edge global contract research company.'
Molecular Profiles was founded in 1997 as an independent spin-off company from the School of Pharmacy at the University of Nottingham. The Queen's Award for Enterprise was also awarded to the University's School of Pharmacy, for its world leading pharmaceutical research.